DTIC-DOME
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DTIC-DOME is a small-molecule injectable chemotherapy approved in 1975 for thyroid cancer. The mechanism of action is not explicitly documented in available data, but it represents a legacy cytotoxic agent from the classical chemotherapy era. It is administered by injection and competes in a modern landscape dominated by targeted tyrosine kinase inhibitors and radiopharmaceuticals.
LOE Approaching
As a legacy product approaching loss of exclusivity with minimal linked commercial roles, this brand likely operates under a mature, small team focused on maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DTIC-DOME presents minimal career growth opportunity, with zero linked job openings and an LOE-approaching lifecycle stage. Roles on this product are focused on portfolio maintenance, reimbursement defense, and managed decline rather than expansion or innovation.
Brand Manager (Legacy)Market Access Specialist
Worked on DTIC-DOME at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.